The U.S. Food and Drug Administration announced on October 5, 2026, that it is seeking public input to support ibogaine research. Its request for information asks for comments, data and evidence about how early-phase clinical trials of ibogaine drug products could be designed, with particular attention to patient safety.
The FDA announcement describes research approaches under consideration, rather than a treatment plan for patients. The agency says the information it receives may help clarify ibogaine’s potential uses, benefits and risks and inform drug development.
What the FDA wants to learn about ibogaine research
The request covers several elements of clinical trial protocols: dose selection and escalation, the setting where care would occur, safety monitoring, participant eligibility, stopping rules and safety oversight. These are questions about how research should be conducted and supervised.
The FDA groups its request into four main areas:
- General study design: Which patient populations would be appropriate for research.
- Dose selection and escalation: How available evidence should guide starting doses and small groups studied sequentially at increasing doses.
- Safety considerations: Monitoring for cardiac and neurologic adverse events, along with other trial safeguards.
- Ethics and oversight: Informed consent and appropriate independent safety oversight.
The announcement emphasizes both important scientific questions and serious safety concerns. It also recognizes the unmet needs of patients whose serious conditions have not responded to existing treatments. The agency is asking for high-quality information to inform research while putting patient safety first.
Who may be affected
The announcement is relevant to people following research into opioid use disorder, post-traumatic stress disorder and alcohol use disorder, as well as researchers and other stakeholders interested in clinical trial design. HHS is prioritizing two initial populations for federally supported research: adults with opioid use disorder and adults with PTSD.
The FDA also reports that it has allowed an early-phase study of noribogaine hydrochloride, a derivative of ibogaine, to proceed under an Investigational New Drug application as a potential treatment for alcohol use disorder. That study is distinct from the request for public input on ibogaine trial design.
The notice does not establish benefits for these conditions. It describes efforts to collect evidence and better understand potential benefits and risks.
Safety safeguards are directed at clinical research
The agency’s safety discussion focuses on safeguards within trials, including cardiac and neurologic monitoring, eligibility criteria, stopping rules, informed consent and independent oversight. These are research considerations, not instructions for readers to use ibogaine or select a dose.
The announcement does not provide individual treatment recommendations or at-home safety steps. Readers looking for the agency’s specific proposed protocol elements should consult the official notice rather than treating this summary as medical guidance.
How this fits into federal research efforts
The FDA says the request follows President Trump’s April 2026 executive order on accelerating medical treatments for serious mental illness. In July 2026, the agency also finalized its guidance, Psychedelic Drugs: Considerations for Clinical Investigations, for sponsors developing psychedelic drugs.
Other federal efforts include an HHS program funded through the Advanced Research Projects Agency for Health to collect safety and efficacy data in early-phase trials. The National Institute on Drug Abuse is funding research on ibogaine’s potential use for opioid use disorder.
When to consult the official notice
Consult the linked FDA announcement if you want to submit comments, review the proposed research topics or check submission instructions. The agency states that the public has 45 days following publication in the Federal Register to provide comments, data or information.
The stated deadline is Friday, November 20, 2026. Late comments will not be considered. Electronic submissions can be made at regulations.gov by searching for Docket No. FDA-2026-N-10429. The announcement also provides an address for written submissions.
Frequently Asked Questions
What is the FDA asking the public to provide?
Comments, data and information on early-phase ibogaine trial design, including participant selection, dosing approaches, safety safeguards and oversight.
Which populations are priorities for federally supported research?
HHS identifies adults with opioid use disorder and adults with PTSD as its two initial priority populations.
When does the public comment period close?
The FDA lists November 20, 2026, as the deadline and says late comments will not be considered.
